CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,369 | +70.7% | 1,330 | +111.1% | 0.00% | +100.0% |
| Q2 2023 | $35,368 | +24.1% | 630 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $28,495 | +109496.2% | 630 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $26 | -99.9% | 630 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $41,000 | +7.9% | 630 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $38,000 | -5.0% | 630 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $40,000 | -16.7% | 630 | -0.2% | 0.00% | 0.0% |
| Q4 2021 | $48,000 | -39.2% | 631 | -10.6% | 0.00% | -50.0% |
| Q3 2021 | $79,000 | -57.8% | 706 | -38.9% | 0.00% | -60.0% |
| Q2 2021 | $187,000 | +32.6% | 1,156 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $141,000 | -33.2% | 1,156 | -15.9% | 0.00% | -42.9% |
| Q4 2020 | $211,000 | +627.6% | 1,375 | +292.9% | 0.01% | +600.0% |
| Q3 2020 | $29,000 | +11.5% | 350 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $26,000 | +73.3% | 350 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $15,000 | -28.6% | 350 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $21,000 | – | 350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |